DURAGESIC-25
Clinical safety rating
cautionComprehensive clinical and safety monograph for DURAGESIC-25 (DURAGESIC-25).
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
| Metabolism | Primarily metabolized via CYP3A4 to norfentanyl (major inactive metabolite) and other minor metabolites. |
| Excretion | Renal (75% as metabolites, <10% unchanged); fecal (9%) |
| Half-life | Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment |
| Protein binding | ~80-85% bound to plasma proteins (mainly albumin, also alpha-1-acid glycoprotein) |
| Volume of Distribution | 6-10 L/kg (large, indicating extensive tissue distribution; Vd 6.4 L/kg in adults) |
| Bioavailability | Transdermal: ~92% absolute bioavailability (fentanyl absorbed through skin; compared to IV administration) |
| Onset of Action | Transdermal: 12-24 hours to achieve steady-state; initial analgesia may require 12-24 h after first application |
| Duration of Action | Transdermal: 72 hours (steady-state maintained during wear; residual absorption continues up to 24 h after removal) |
| Molecular Weight | 336.47 |
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | For GFR 10-50 mL/min: start with 12 mcg/hour patch; for GFR <10 mL/min: avoid use due to accumulation of active metabolite; consider alternative therapy. |
| Liver impairment | Child-Pugh Class A or B: reduce starting dose by 50% (e.g., start with 12 mcg/hour); Child-Pugh Class C: avoid use or use with extreme caution and close monitoring. |
| Pediatric use | For children aged 2-16 years: initial dose based on opioid tolerance; typical starting dose for opioid-naive: 25 mcg/hour transdermal patch every 72 hours is not recommended; use lower strength or immediate-release opioids; refer to institutional guidelines. |
| Geriatric use | Start at lowest available strength (12 mcg/hour) and titrate cautiously; monitor for respiratory depression and constipation; avoid in frail elderly if possible. |
| 1st trimester | Associated with neural tube defects and congenital malformations; use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal dependence and withdrawal; use only if clearly needed. |
| 3rd trimester | Risk of neonatal opioid withdrawal syndrome (NOWS); prolonged use may cause respiratory depression in neonate. |
Clinical note
Comprehensive clinical and safety monograph for DURAGESIC-25 (DURAGESIC-25).
| Placental transfer | Fentanyl crosses the placenta rapidly; detected in fetal circulation within minutes of maternal administration. Degree of transfer is high due to lipophilicity. |
| Breastfeeding | Fentanyl is excreted into breast milk in low concentrations; however, with transdermal patches, maternal serum levels are sustained, leading to potential infant exposure. Avoid breastfeeding while using Duragesic-25 due to risk of infant sedation and respiratory depression. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Limited human data; animal studies show increased risk of malformations at high doses. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid unless benefits outweigh risks. |
| Fetal Monitoring | Monitor maternal vital signs (heart rate, blood pressure, respiratory rate), pain scores, and signs of opioid toxicity. Fetal monitoring (non-stress test, biophysical profile) if prolonged use. Neonatal monitoring for withdrawal symptoms after delivery. |
| Fertility Effects | Opioid use may impair fertility via hormonal disruptions (e.g., altered gonadotropin release). Reversible upon discontinuation. Specific data on Duragesic-25 limited. |
■ FDA Black Box Warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DURAGESIC. Ensure accuracy when prescribing, dispensing, and administering DURAGESIC. Dosage errors can result in accidental overdose or death. Concomitant use with CYP3A4 inhibitors, potent CYP3A4 inducers, or the cessation of CYP3A4 inducers can cause fatal respiratory depression. DURAGESIC is contraindicated in opioid-non-tolerant patients and in acute or postoperative pain.
| Serious Effects |
Hypersensitivity to fentanyl or any component of the patchAcute or postoperative pain (short-term use)Concurrent use of MAO inhibitors or within 14 days of discontinuationSignificant respiratory depressionKnown or suspected paralytic ileus
| Precautions | Life-threatening respiratory depression, Accidental exposure to children, Neonatal opioid withdrawal syndrome, Risks from concomitant use with benzodiazepines or other CNS depressants, Interaction with alcohol, Adrenal insufficiency, Hypotension and bradycardia, Severe hypotension, Risks in patients with gastrointestinal obstruction, Seizures in patients with seizure disorders, Life-threatening QT prolongation at high doses |
| Food/Dietary | Avoid alcohol and other CNS depressants (e.g., benzodiazepines) as they increase the risk of respiratory depression and sedation. No specific food interactions; however, grapefruit juice may theoretically increase fentanyl levels via CYP3A4 inhibition, but clinical significance is minimal. Advise patients to maintain consistent dietary habits. |
| Clinical Pearls | DURAGESIC-25 delivers fentanyl at 25 mcg/h transdermally. The reservoir system may leak if cut, potentially causing fatal overdose. Apply to non-irritated, non-hairy skin on upper torso. Do not apply heat sources (heating pads, hot tubs) as they increase absorption rate. Onset of action is 12-24 hours; titrate no more frequently than every 3 days. Use only in opioid-tolerant patients due to risk of respiratory depression. Monitor for serotonin syndrome if co-administering serotonergic drugs. |
| Patient Advice | Apply the patch to clean, dry, non-hairy skin on the upper body; change every 72 hours. · Do not cut, tear, or damage the patch; do not use if the pouch seal is broken. · Avoid exposing the patch area to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sun exposure. · Keep patches out of reach of children and pets; dispose of used patches by folding adhesive sides together and flushing down the toilet. · Do not stop using this medication abruptly; withdrawal may occur. |
Loading safety data…